Healthcare costs and resource utilization of asthma in Germany: a claims data analysis
-
Published:2015-02-26
Issue:2
Volume:17
Page:195-201
-
ISSN:1618-7598
-
Container-title:The European Journal of Health Economics
-
language:en
-
Short-container-title:Eur J Health Econ
Author:
Jacob Christian,Bechtel Benno,Engel Susanne,Kardos Peter,Linder Roland,Braun Sebastian,Greiner Wolfgang
Abstract
Abstract
Introduction
Asthma is associated with a substantial economic burden on the German Statutory Health Insurance.
Aims and objectives
To determine costs and resource utilization associated with asthma and to analyze the impact of disease severity on subgroups based on age and gender.
Methods
A claims database analysis from the statutory health insurance perspective was conducted. Patients with an ICD-10-GM code of asthma were extracted from a 10 % sample of a large German sickness fund. Five controls for each asthma patient matched by age and gender were randomly selected from the same database. Costs and resource utilization were calculated for each individual in the asthma and control group. Incremental asthma-related costs were calculated as the mean cost difference. Based on prescribed asthma medication, patients were classified as intermittent or persistent. In addition, age groups of ≤5, 6–18, and >18 years were analyzed separately and gender differences were investigated.
Results
Overall, 49,668 individuals were included in the asthma group. On average, total annual costs per patient were €753 higher (p = 0.000) compared to the control group (€2,168 vs. €1,415). Asthma patients had significantly higher (p = 0.000) outpatient (€217), inpatient (€176), and pharmacy costs (€259). Incremental asthma-related total costs were higher for patients with persistent asthma compared to patients with intermittent asthma (€1,091 vs. €408). Women aged >18 years with persistent asthma had the highest difference in costs compared to their controls (€1,207; p < 0.0001). Corresponding healthcare resource utilization was significantly higher in the asthma group (p = 0.000).
Conclusions
The treatment of asthma is associated with an increased level of healthcare resource utilization and significantly higher healthcare costs. Asthma imposes a substantial economic burden on sickness funds.
Publisher
Springer Science and Business Media LLC
Subject
Health Policy,Economics, Econometrics and Finance (miscellaneous)
Reference26 articles.
1. Schlaud, M., Atzpodien, K., Thierfelder, W.: Allergic diseases. Results from the German Health Interview and Examination Survey for Children and Adolescents (KiGGS). Bundesgesundheitsblatt. Gesundheitsforschung. Gesundheitsschutz. 50(5–6), 701–710 (2007) 2. Stock, S., Redaelli, M., Luengen, M., Wendland, G., Civello, D., Lauterbach, K.W.: Asthma: prevalence and cost of illness. Eur. Respir. J. 25(1), 47–53 (2005) 3. Hasford, J., Uricher, J., Tauscher, M., Bramlage, P., Virchow, J.C.: Persistence with asthma treatment is low in Germany especially for controller medication—a population based study of 483,051 patients. Allergy. 65(3), 347–354 (2010) 4. von, M.E., Martinez, F.D., Fritzsch, C., Nicolai, T., Roell, G., Thiemann, H.H.: Prevalence of asthma and atopy in two areas of West and East Germany. Am.J.Respir.Crit Care Med. 149(2 Pt 1), 358–364 (1994) 5. Nowak, D., Volmer, T., Wettengel, R.: Asthma bronchiale—eine Krankheitskostenanalyse. Pneumologie. 50, 364–371 (1996)
Cited by
33 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|